Aligos Therapeutics, Inc. · NASDAQ:ALGS
Aligos Therapeutics — Investor Presentation (November 2023)
36 slides from Aligos Therapeutics's investor presentation, November 2023
Slide 1: Corporate Presentation November 2023
Lawrence M. Blatt, Ph.D. Chairman, CEO & Co-Founder C Corporate Presentation November 2023
Slide 2: Disclosures
Disclosures This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and f
Slide 3: Aligos Development Portfolio
Aligos Development Portfolio Multiple Milestones/Data Readouts Anticipated in 2023/2024 Candidate Indication MOA 2023/2024 Clinical Trial Timelines and Data Readouts Q4 2023 Q1 2024 Q2 2024 Q3 2024 Ph2a filing THR-β Phase 2 Phase 2a ALG-055009 Enabling Activities (12 week MRI-PDFF in NASH) Agonist N
Slide 4: NASH
NASH • ALG-055009, small molecule THR-β agonist 3
Slide 5: Thyroid Hormone Receptors Alpha and Beta
Thyroid Hormone Receptors Alpha and Beta Thyroid hormone Thyroid hormone receptor beta (THR-β) receptor alpha (THR-α) Liver Heart, skeletal muscle Positive effects Negative effects • Regulates lipid metabolism • Increase cardiac work • Decreased LDL, Cholesterol, • Heart rate elevation Triglycerides
Slide 6: ALG-055009 Best In Class Potential vs. 1st Generation THR-β Agonists
ALG-055009 Best In Class Potential vs. 1st Generation THR-β Agonists Parameter Resmetirom TERN-501 VK-2809 ALG-055009 THR-β potency** (EC50 <1 µM HEK293T cell-based assay) X X Efficacy Lipid lowering in DIO mouse model* >70% of patients with >30% change from baseline in MRI-PDFF in Phase
Slide 7: Analysis of Competitor Data
Analysis of Competitor Data 6
Slide 8: PK (Day 14) Data Resmetirom vs. VK-2809 and TERN-501
PK (Day 14) Data Resmetirom vs. VK-2809 and TERN-501 Resmetirom – Non-Linear PK VK-2809 – Linear PK Dose (mg) 0.25 1 2.5 5 10 20 40 TERN-501 – Linear PK MAD data at Day 14 from Taub et al, Atherosclerosis, 2013, Lian et al., ACC 2016 and Nelson et al., EASL 2022. 7
Slide 9: ALG-055009 Comparison to Resmetirom, TERN-501 and VK-2809
ALG-055009 Comparison to Resmetirom, TERN-501 and VK-2809 Parameter Resmetirom TERN-501 VK-2809 ALG-055009 THR-β cell-based agonism 2370 1750 267 50 (EC50 HEK293T cell-based assay, nM) PK - half life (t1/2) Short Long Long Long PK - linearity Nonlinear Linear Linear Linear Potency (
Slide 10: Resmetirom Phase 3 Data
Resmetirom Phase 2 Data Liver Biopsy 70 Resmetirom Treated 60 50 % Response 40 30 20 10 0 NASH Resolution Fibrosis Reduction Both NR and (NR) Fibrosis reduction >50% PDFF ≥30% PDFF MRI-PDFF Non-Responder Non-Responder: <30% fat reduction on Week 12 MRI-PDFF MRI-PDFF de-fatting correlated with histol
Slide 11: ALG-055009 Phase 1 Study Design
ALG-055009 Phase 1 Study Design Part 1: Single Ascending Dose (SAD) Part 2: Multiple Ascending Dose (MAD) – Dosing PO QD X 14 days Part 3: Relative Bioavailability, Food Effect (Gel Cap) N = up to 64 Healthy Volunteers N = up to 80 Subjects with Hyperlipidemia N = 8 per Cohort, N = 6 ALG-055009 and
Slide 12: Part 1: Single Ascending Dose - PK, Safety, Biomarkers
Study ALG-055009-301 Part 1: Single Ascending Dose - PK, Safety, Biomarkers • Oral doses evaluated: 0.1, 0.3, 0.9, 2.6, 4.0 mg • PK – Dose proportional, with low variability – t1/2 = 20-24 hours (supports once daily (QD) dosing) • Safety: well tolerated – No serious adverse events (SAEs), Grade ≥3 t
Slide 13: Part 2: Multiple Ascending Dose - PK, Safety
Study ALG-055009-301 Part 2: Multiple Ascending Dose - PK, Safety • Oral doses evaluated: 0.3, 0.5, 0.6, 0.75 and 1.0 mg QD x 14 days • PK: favorable profile (dose-proportional, low variability (≤30%), 2x accumulation) • Safety: well tolerated, no clinical evidence of hypo or hyperthyroidism – No SA
Slide 14: Multiple Ascending Dose - Biomarkers: SHBG
Multiple Ascending Dose - Biomarkers Part 2: Expected Thyromimetic Effects Observed Dosing Period Generally dose proportional increases in SHBG Charfi et al., AASLD 2022. clinicaltrials.gov; NCT05090111. 13
Slide 15: Multiple Ascending Dose - Biomarkers: Lipids
Multiple Ascending Dose - Biomarkers Part 2: Expected Thyromimetic Effects Observed Day Dose responsive reductions in lipids (e.g., LDL, Apo-B, Triglycerides) Charfi et al., AASLD 2022. clinicaltrials.gov; NCT05090111. 14
Slide 16: Formulation / Food Effect Part 3
Formulation / Food Effect Part 3: PK Data Comparison in Healthy Volunteers at 0.6 mg Dose = 0.6 mg Gel cap vs. liquid formulation: similar (~86%) PK with low variability, no food effect Phase 2 formulation (gel cap) confirmed 15
Slide 17: ALG-055009 Preliminary Phase 2 Study Design
ALG-055009 Preliminary Phase 2 Study Design Dose #1 (low) ALG-055009 (N~20) Dose #2 ALG-055009 (N~20) Randomize Dose #3 ALG-055009 (N~20) Dose #4 (high) ALG-055009 (N~20) Placebo (N~20) Day 1 Week 12 Week 16 Treatment Period Follow-up Period (PO QD x 12 weeks) (4 weeks) • Population: Adults subjects
Slide 18: ALG-055009 Summary
ALG-055009 Summary • Discovered by Aligos – issued US patent expires 2040 • More β-selective, ~5-50 fold more potent than competitor THR-β drugs • Phase 1 – Safety – well tolerated without clinical safety signals – PK – favorable profile (linear, low variability) that is differentiated vs. resmetiro
Slide 19: Chronic Hepatitis B
ALIGOS THERAPEUTICS Chronic Hepatitis B
Slide 20: Therapeutic Approaches to CHB Functional Cure
Therapeutic Approaches to CHB Functional Cure Inhibit Viral Replication Lower Antigen Burden Boost Immune Response 19
Slide 21: Inhibiting Viral Replication
Inhibiting Viral Replication • ALG-000184 (CAM-E) 20
Slide 22: ALG-000184 Superior Potency vs. Competitor CAM-Es
ALG-000184 Superior Potency vs. Competitor CAM-Es HBV DNA reduction Compound Current Status Cell Type (EC50 nM) 0.63 HepG2.117 Aligos ALG-000184 Phase 1 0.53 HepG2.2.15 Assembly ABI-4334 Phase 1 1.2 AD38 Enanta EDP-514 Phase 1 17 HepG2.115 Assembly ABI-H3733 Partnered, BeiGene 5 AD38 Vebicorvir Disc
Slide 23: ALG-000184-201 Phase 1 Study – Summary of Parts 1, 2 & 3
ALG-000184-201 Phase 1 Study – Summary of Parts 1, 2 & 3 • Parts 1 and 2 – SAD and MAD (7 days) in healthy volunteers completed – Well tolerated with excellent PK • Part 3 – 28-day monotherapy in untreated HBeAg- (10, 50, 100 mg) and HBeAg+ (10, 100, 300 mg) CHB subjects completed – Well tolerated w
Slide 24: ALG-000184 Antiviral Activity vs. Competitor CAMs (HBeAg Negative)
ALG-000184 Antiviral Activity vs. Competitor CAMs (HBeAg Negative*)** HBV DNA Drug Name Current Status Dose Mean Decline from BL to EOT % < LLOQ at Day 28 (Log10 IU/mL) ALG-000184 Phase 1 10 mg 3.7 100 ABI-H07311,2 Phase 2a 300 mg 2.5 25 JNJ-63793,4 Phase 2 250 mg 2.7 56 200 mg 2.9 N/A EDP-5145 Phas
Slide 25: Part 4 Cohort 2 (300 mg ALG-000184 + ETV x 48 Weeks)
ALG-000184-201 Part 4 Cohort 2 (300 mg ALG-000184 + ETV x 48 Weeks) Randomize N=8 3 active:1 placebo Follow-up (+ ETV) 300 mg ALG-000184 + ETV x 48 weeks Cohort 2 x 8 weeks HBeAg (+) N=15 Placebo + ETV N=2 300 mg ALG-000184 mg + ETV Follow-up (+ ETV) Fully enrolled x 12 weeks x 48 weeks x 8 weeks Do
Slide 26: Part 4 Cohort 2 HBeAg+ Mean HBV DNA Declines
Part 4 Cohort 2, 300 mg ALG-000184 + ETV x 48 weeks, HBeAg+ Mean HBV DNA Declines in Subjects Receiving ALG-000184 x ≥12 Weeks Time (Weeks) 300 mg ALG-000184 + ETV x ≥20 weeks resulted in mean DNA reductions of ≥6 log10 IU/mL The addition of 300 mg ALG-000184 at Week 12 in subjects initially receivi
Slide 27: Part 4 Cohort 2 HBeAg+ HBsAg Declines
Part 4 Cohort 2, 300 mg ALG-000184 + ETV x 48 weeks, HBeAg+ HBsAg Declines in Subjects Receiving ALG-000184 x ≥12 Weeks 300 mg ALG-000184 + ETV Dosed ≥12 weeks (N=12): 7 of 12 subjects had decline of at least ~0.4 log10 IU/mL Dosed ≥24 weeks (N=7): 4 of 7 subjects had decline of ≥1 log10 IU/mL Maxim
Slide 28: ALG-000184 Multiple Development Paths Available
ALG-000184 Multiple Development Paths Available Endpoint Affected Viral Markers Approvable Endpoint* In Functional Cure HBsAg, DNA China, US, EMEA Partial Cure HBsAg, DNA TBD DNA Suppression DNA China, US, EMEA (Used for tenofovir alafenamide (TAF) approval) *Endpoints defined in regulatory guidance
Slide 29: ALG-000184-201 Part 4 Interim Data
ALG-000184-201 - Part 4 Interim Data Superior Antiviral Activity with a Favorable Safety Profile • Safety – well tolerated • Significant antiviral activity in HBeAg+ subjects in combination with ETV – Significant antiviral activity for ALG-000184 + ETV compared with ETV alone – 4/7 subjects dosed x
Slide 30: Coronavirus
Coronavirus • ALG-097558 (CoV Protease Inhibitor) 29
Slide 31: ALG-097558 Aligos' Potent COVID-19 Protease Inhibitor
ALG-097558 Aligos’ Potent COVID-19 Protease Inhibitor • Despite the availability of prophylactic vaccines, a need for therapeutics still exists – New variants are continuously emerging – Large segments of global population lack access to, or are opposed to, vaccination – Especially needed to prevent
Slide 32: ALG-097558 Best In Class Potential vs. other Oral Protease Inhibitors
ALG-097558 Best In Class Potential vs. other Oral Protease Inhibitors Aligos Pfizer Shionogi Sorrento Enanta Parameters ALG-097558 Nirmatrelvir/RTV Ensitrelvir Olgotrelvir EDP-235 (preclinical) (authorized – global) (authorized – Japan) (Phase 3) (Phase 2) SARS-CoV-2 variants/subvariants*
Slide 33: ALG-097558 Phase 1 Safety & PK
ALG-097558 Phase 1 Safety & PK – Dosing in Healthy Volunteers Initiated Part 1: Part 2: Part 3: Single Ascending Multiple Ascending Midazolam Dose/Food Effect Dose Drug-Drug Interaction (Ongoing) Part 4: Itraconazole Drug-Drug Interaction Part 5 (OPTIONAL): Carbamazepine Drug-Drug Interaction Part 6
Slide 34: ALG-097558 Coronavirus Protease Inhibitor Drug Candidate
ALG-097558 Coronavirus Protease Inhibitor Drug Candidate • Potent pan-coronavirus protease inhibitor drug candidate – Additional candidates from the series advancing as backup compounds • Superior preclinical profile versus nirmatrelvir (Pfizer) – 6-27 fold more potent in biochemical and cell-based
Slide 35: Executive Summary
Executive Summary Aligos Advancing Multiple Promising Drugs in Areas of Unmet Need • NASH – ALG-055009 (THR-β agonist) - enhanced PK, pharmacology vs. competitor THR-β drugs; US IND cleared – Phase 2a study with ALG-055009 (12-week MRI-PDFF) - filing Q4 2023, Topline data Q4 2024 – Oligonucleotide e
Slide 36: Aligos Therapeutics
ALIGOS THERAPEUTICS
Aligos Therapeutics — Investor Presentation (November 2023) on 6ix